Close Menu
Strong instrument sales, especially in its newly refreshed mass-spectrometry portfolio, fueled a 14-percent jump in total sales for the first quarter, Waters reported this week.
 
CEO Douglas Berthiaume also hinted that the company may make an acquisition sometime this year.
 
Shipments of the company’s mass specs rose 12 percent year-over-year, helping overall sales climb to $331 million for the three months ended March 31, compared to $290 million a year ago.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.